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in Pancreatic Cancer Cells
Aditi Jain1, University of Nebraska-Lincoln Undergraduate Student, Sanchita Rauth1, PhD Student, Dr. Surinder K. Batra1, PhD,
Dr. Moorthy P. Ponnusamy1, PhD
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198
• Pancreatic cancer (PC), a highly aggressive human cancer, is the third 
leading cause of death due to cancer, with a five-year survival rate1. 
• Cancer stem cells (CSCs) are a small and distinct population of cancer 
cells that mediate tumorigenesis, metastasis and resistance to standard 
treatments1. 
• Specifically identifying and targeting CSC maintenance genes can improve 
the efficiency of treatment modalities5. 
• PAF1 (RNA Polymerase II-Associated Factor 1), also known as PD2 
(Pancreatic Differentiation 2), is the core subunit of the human PAF1 
complex (PAF1C). It maintains pluripotency of stem cells and is a marker 
of pancreatic CSCs2 3.
• PAF1/PD2 is upregulated in poorly differentiated pancreatic cancer cells2.
• Gemcitabine (Gem) is a novel deoxycytidine analogue developed as an 
anticancer therapy4. It is widely used as a chemotherapeutic agent and is 
presently the most effective agent against pancreatic cancer5.  
• Identify the specific inhibitor for PAF1/PD2 using an In-silico analysis 
• Test the efficacy of PAF1/PD2 inhibitor in cancer stem cell and drug resistant models
• Investigate the therapeutic efficacy of PAF1/PD2 inhibitor along with gemcitabine using 
preclinical models
• PAF1/PD2 are over expressed in Pancreatic Tumor cells, specifically in 
cancer stem cells (CSCs).
• Increased expression of PAF1/PD2 is associated with gemcitabine 
resistance in pancreatic cancer cells. 
• The knockdown of PAF1/PD2 leads to a significant reduction in expression 
of CSC markers and pancreatic tumorigenesis.
• Human pancreatic tumor samples showed increased expression of 
PAF1/PD2. Additionally, altered expression of PAF1/PD2 has prognostic 
relevance to pancreatic cancer patient survival. 
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PAF1/PD2 plays a role in the maintenance of Pancreatic cancer stem cells 












































Fig.1: A) Western blot depicting the Gemcitabine treated population exhibiting a higher expression of CD44 and PAF1/PD2 in comparison to the control 
population. B) Western blot depicting SP cells exhibiting a higher expression of PAF1, MDR1 and CD44 in comparison to NSP cells. C) Addition of 
Gemcitabine caused a significant increase in the expression of CSC markers (PAF1, ABCB1, CXCR4, CD133, ALDH1, and ZO-1). D) Confocal 
microscopy analysis of a Gemcitabine resistant population which shows a higher expression compared to the control population in MIAPaCa2 and 
SW1990 PC cell lines. 
Fig.2: A) MTT Assay depicting the knockdown of PAF1/PD2 leading to a decrease in the MIAPaCa2 PC cell line as compared to the control and Gemcitabine resistant 
populations. B) In vitro colony formation tumorigenesis assay performed using 1.0 x 103 PC cells which were fixed and stained after 14 days in culture. C) Cell 
proliferation analysis displaying a decrease in cells in PAF1/PD2 knockdown compared to the control group. D) Apoptotic Assay depicting higher cell death with 
PAF1/PD2 knockdown. 
Fig.3: A) ) Knockdown of PAF1/PD2 led to a decrease in the expression of CSC markers (PAF1, CXCR4, ZO-1, CD133, WNT5A, and 
MMPI) B) Fluorescent activated cell-sorting (FACS) analysis of PC cells stained with soluble Hoescht dye in order to determine % of 
population of Pancreatic CSCs (side population analysis).  C) and D) Sphere Assay analysis depicts the knockdown of PAF1/PD2 
significantly caused a decrease in the MIAPaCa2 PC cell line in comparison to the control and Gemcitabine resistant populations. E) 
Confocal microscopy analysis of a PAF1/PD2 knockdown population which shows a lower expression of MDR1 and β-catenin compared 







Fig. 4: A) Data obtained from cBioPortal demonstrating that 5% of PC patients out of 100 were shown to have higher levels of PAF1. B) Data obtained 
from Gepia demonstrating that tumor patients had higher levels of PAF1/PD2 in comparison to normal patients. C)  The survival rate comparison 
between the altered group (samples with at least one alteration in PAF1 in PC patients) and unaltered group (samples without any alterations in PAF1 in 
PC patients) over a period of 178 months. D) Composite score comparison of PAF1/PD2 between normal/benign tumor vs. malignant tumor depicting 


















PAF1 KD cells 
sensitive to 
Gemcitabine and 




analysis show increased 













Gemcitabine increases expression of PAF1/PD2 and 
CSC Markers
Impact of PAF1/PD2 on Gemcitabine Resistance 
and CSC marker expression 
Loss of PAF1/PD2 influences maintenance of PC cells and 
sensitizes the cells to Gemcitabine 
Impact of PAF1/PD2 on Human Pancreatic tumor samples
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